{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:49:32Z","timestamp":1761490172153},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Cytomegalovirus (CMV) is a frequent complication of hematopoietic stem cell transplant in pediatric patients, with significant morbidity and mortality. Antiviral drugs are used as prophylactic, preemptive or therapeutic medicines; however, no uniform guidelines exist for the best strategy to prevent CMV disease. Resistance to standard antiviral therapies can lead to further difficulty in managing CMV disease. Studies for investigational therapies are underway and could provide options for treatment of resistant CMV, while limiting toxicities associated with currently used antiviral therapies.<\/jats:p>","DOI":"10.1097\/mph.0000000000000730","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T03:44:34Z","timestamp":1483674274000},"page":"241-248","source":"Crossref","is-referenced-by-count":18,"title":["Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients"],"prefix":"10.1097","volume":"39","author":[{"given":"Bethany A.","family":"Wattles","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Norton Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital Colorado, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra C.","family":"Cheerva","sequence":"additional","affiliation":[{"name":"Pediatric Cancer and Blood Disorders, University of Louisville, Louisville, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Lucas","sequence":"additional","affiliation":[{"name":"Pediatric Cancer and Blood Disorders, University of Louisville, Louisville, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Norton Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mph.0000174242.80167.9d","article-title":"Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment","volume":"27","author":"Patel","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20230918","article-title":"Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients","author":"Wu","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2002-10-3263","article-title":"Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis","volume":"102","author":"Ljungman","year":"2003","journal-title":"Blood"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/tid.12238","article-title":"A single-center experience of cytomegalovirus infections in Asian pediatric patients undergoing allogeneic hematopoietic stem cell transplant for leukemia in Singapore","volume":"16","author":"Tan","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/infdis\/153.3.478","article-title":"Risk factors for cytomegalovirus infection after human marrow transplantation","volume":"153","author":"Meyers","year":"1986","journal-title":"J Infect Dis"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbmt.2009.08.006","article-title":"Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients","volume":"15","author":"Satwani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bmt.2013.164","article-title":"Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT","volume":"49","author":"Bontant","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/bmt.2015.303","article-title":"Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood","volume":"51","author":"Solano","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"ofw107","DOI":"10.1093\/ofid\/ofw107","article-title":"Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients","volume":"18","author":"Navarro","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/tid.12539","article-title":"Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Ju","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R19-20230918","first-page":"462","article-title":"Prophylactic acyclovir and preemptive ganciclovir to prevent cytomegalovirus disease in children after hematopoietic stem cell transplant","volume":"12","author":"Tavil","year":"2014","journal-title":"Exp Clin Transplant"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/pbc.21043","article-title":"A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients","volume":"49","author":"Shereck","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1399-3062.2012.00760.x","article-title":"Cytomegalovirus infection and ganciclovir resistance caused by ul97 mutations in pediatric transplant recipients","volume":"14","author":"Kim","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00002030-199612000-00006","article-title":"Filgrastim to treat neutropenia and support myelosuppressive medication dosing in hiv infection. G-CSF 92105 Study Group","volume":"10","author":"Hermans","year":"1996","journal-title":"AIDS"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1182\/blood.V77.10.2109.2109","article-title":"Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine","volume":"77","author":"Miles","year":"1991","journal-title":"Blood"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1705341","article-title":"Valganciclovir is safe and effective as pre-emptive therapy for cmv infection in allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Ayala","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bmt.1705311","article-title":"Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients","volume":"37","author":"Van der Heiden","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1399-3062.2006.00183.x","article-title":"Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation","volume":"9","author":"Busca","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MPH.0000000000000397","article-title":"Oral valganciclovir as preemptive therapy for cytomegalovirus reactivation in pediatric hematopoietic stem cell transplant patients","volume":"37","author":"Atay","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/petr.12030","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients","volume":"17","author":"Villeneuve","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/01.tp.0000209195.95115.8e","article-title":"Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients","volume":"81","author":"Yusuf","year":"2006","journal-title":"Transplantation"},{"key":"R38-20230918","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/44.2.97","article-title":"Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys","volume":"44","author":"Lacy","year":"1998","journal-title":"Toxicol Sci"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","article-title":"Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation","volume":"318","author":"Meyers","year":"1988","journal-title":"N Engl J Med"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European acyclovir for CMV prophylaxis study group","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.bmt.1704463","article-title":"High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation","volume":"33","author":"Hazar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-109-10-777","article-title":"Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin","volume":"109","author":"Emanuel","year":"1988","journal-title":"Ann Intern Med"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-109-10-783","article-title":"Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants","volume":"109","author":"Reed","year":"1988","journal-title":"Ann Intern Med"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00007890-198812000-00022","article-title":"Ganciclovir\/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients","volume":"46","author":"Schmidt","year":"1988","journal-title":"Transplantation"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/clinids\/14.4.831","article-title":"Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of european bone marrow transplant group","volume":"14","author":"Ljungman","year":"1992","journal-title":"Clin Infect Dis"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.30.6.554","article-title":"Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"30","author":"Alexander","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1700649","article-title":"No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group","volume":"19","author":"Ruutu","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/infdis\/164.3.483","article-title":"Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant","volume":"164","author":"Bowden","year":"1991","journal-title":"J Infect Dis"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1083-8791(01)80005-7","article-title":"Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Boeckh","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.1373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/14653249.2012.662769","article-title":"The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation","volume":"14","author":"Sellar","year":"2012","journal-title":"Cytotherapy"},{"key":"R54-20230918","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"R55-20230918","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8\u00fe T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"R56-20230918","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"R57-20230918","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1469-0691.12449","article-title":"Cytomegalovirus vaccine: phase II clinical trial results","volume":"5","author":"Rieder","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R58-20230918","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"R59-20230918","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/INF.0b013e318182026f","article-title":"Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution","volume":"28","author":"Horn","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R60-20230918","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The clinical and financial burden of preemptive management of CMV disease after allogeneic stem cell transplantation\u2014implications for preventative treatment approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"key":"R61-20230918","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.bbmt.2008.07.014","article-title":"Expansion of cytomegalovirus pp65 and IE-I specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation","volume":"14","author":"Bao","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R62-20230918","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood.V96.9.3286","article-title":"Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes","volume":"96","author":"Eckle","year":"2000","journal-title":"Blood"},{"key":"R63-20230918","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1701302","article-title":"Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study","volume":"22","author":"Moretti","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R64-20230918","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"R65-20230918","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ajt.12042","article-title":"The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection","volume":"13","author":"Cunha-Bang","year":"2013","journal-title":"Am J Transplant"},{"key":"R66-20230918","first-page":"237","article-title":"Susceptibility of human cytomegalovirus to two-drug combinations in vitro","volume":"1","author":"Manion","year":"1996","journal-title":"Antivir Ther"},{"key":"R67-20230918","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/TP.0b013e31828555ac","article-title":"Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations","volume":"95","author":"Gracia-Ahufinger","year":"2013","journal-title":"Transplantation"},{"key":"R68-20230918","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"R69-20230918","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R70-20230918","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"R71-20230918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol Blood Marrow Tansplant"},{"key":"R72-20230918","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"Cmx001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"R73-20230918","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201705000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:33:45Z","timestamp":1695011625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201705000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000730","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}